Docteur PASCALE GERARD-MERMET

Rhumatologue

📍 Massy (91)HospitalierRPPS 10001453967

✨ Profil synthétique

IA · 14/05/2026

Le Docteur Pascale Gerard-Mermet est un rhumatologue hospitalier à Massy, auteur de publications sur des sujets variés tels que les essais cliniques, l'épidémiologie et la pharmacovigilance. Ses travaux incluent des revues générales, des méta-analyses et des études sur les traitements anti-IL-17. Ces publications suggèrent une implication dans la recherche et le traitement de maladies rhumatismales.

Expertises présumées

Polyarthrite rhumatoïde
Spondylarthrite ankylosante
Arthrite psoriasique
Traitement anti-IL-17
Essais cliniques en rhumatologie
Épidémiologie des maladies rhumatismales
Pharmacovigilance en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Diplômes

🎓 DES & spécialité ordinale

Rhumatologie (SM)

📚 CES (Certificat d'Études Spéciales)

CES Rhumatologie

🎓 Diplômes

DE Docteur en médecine

Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.

Lieu de consultation

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial

JAMA · 2026

📚 13 citations🎯 RCR 13.00🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Importance Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain. Objective To investigate whether precision immunotherapy guided by the presence of macrophage activation–like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9. Design, Setting, and Participants A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation–like syndrome (blood ferritin &amp;gt;4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and &amp;lt;5000 human leukocyte antigen DR receptors on CD45/CD14 monocytes). The first patient was enrolled August 5, 2021, and the last follow-up, April 29, 2024. Interventions Eligible patients were randomized to receive standard care and precision immunotherapy or standard care and placebo. Those in the precision immunotherapy group with macrophage activation–like syndrome received anakinra intravenously (IV) and placebo subcutaneously, and those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma and IV placebo. Those in the placebo group received both IV and subcutaneous placebo. Treatment was administered for up to 15 days. Main Outcomes and Measures The primary end point was a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure. Key secondary outcomes included 28-day mortality. Results Of 672 patients assessed for eligibility, 281 were randomized and 276 were included in the primary analysis population (mean [SD] age, 70 [13] years; 93 females [33.7%]; median baseline SOFA score, 9 [IQR, 7-11]). The SOFA decrease end point was attained by 46 of 131 patients (35.1%) in the precision immunotherapy group and by 26 of 145 patients (17.9%) in the placebo group (difference, 17.2% [95% CI, 6.8% to 27.2%]; P = .002). Mortality at 28 days was not statistically significantly different between groups. A total of 1069 serious treatment-emergent adverse events (88.8%) were reported; increased incidence of anemia was noted in the anakinra group; and hemorrhage in the recombinant human interferon gamma group. Conclusions and Relevance Among patients with sepsis, precision immunotherapy targeting macrophage activation–like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04990232

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026

Critical care medicine · 2026

📚 4 citations

Reducing Nurse Turnover: A Key Strategy for Lowering Patient Falls and Costs

Nursing administration quarterly · 2026

📚 3 citations🔓 Open Access

Lire l'abstract Crossref ↓

In hospitals, the cost to replace 1 registered nurse (RN) can be quantified by considering costs in recruitment, hiring, and onboarding processes. Though the mean replacement cost of 1 RN will vary depending on geographic location and professional specialization, some have estimated this cost at $56 000. In addition to these direct costs, high turnover also contributes to broader organizational challenges, including disrupted communication, teamwork, and patient care. These challenges can contribute to adverse quality outcomes, such as increased inpatient falls. This article examines the organizational cost of RN turnover by analyzing its relationship to inpatient fall rates as an indicator of quality care.

Cookies & analyse de trafic

Docteur PASCALE GERARD-MERMET

Pourquoi vous devez consulter ce praticien

Diplômes

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal35

Revue générale5

Essai clinique3

Épidémiologie & registres2

Pharmacovigilance2

Revue / méta-analyse2

Anti-IL-171

Biomarqueurs / Auto-Ac1

Case report / série1

Microbiote1

Vraie vie / RWE1

Partager cette fiche